Ultragenyx and mereo biopharma announce new phase 2 data from phase 2/3 orbit study demonstrating sustained reductions in fracture rates following treatment with setrusumab (ux143) in patients with osteogenesis imperfecta (oi)

14-month data show treatment with setrusumab resulted in a large, sustained 67% reduction in annualized fracture rate and persistent median annualized fracture rate of 0.00 (p=0.0014)

OI Ratings Summary

OI Quant Ranking